The Brand Name ANFOE IU Has Generic Salt :: Recombinant
ANFOE IU Is From Company LA RENON Priced :: Rs. 1500
ANFOE IU have Recombinant is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Recombinant||Rs. 1500||1 PFS|
Indications for Drugs ::
Children’s growth disorders, growth hormone deficiency,Turner syndrome, chronic renal failure, Prader-Willi syndrome, intrauterine growth retardation, severe idiopathic short stature
Drug Dose ::
Pediatric Growth Hormone Deficiency (GHD) Generally, a dosage of 0.16 to 0.24 mg/kg body weight /week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections. Prader-Willi Syndrome (PWS) Generally, a dosage of 0.24 mg/kg body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections. Small for Gestational Age (SGA) Generally, a dosage of up to 0.48 mg/kg body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections. Idiopathic Short Stature (ISS) Generally, a dose up to 0.47 mg/kg of body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections. Dosing of Adult Patients Adult Growth Hormone Deficiency (GHD) Based on the weight-based dosing utilized in clinical studies with another somatropin product, the recommended dosage at the start of therapy is not more than 0.04 mg/kg/week given as a daily subcutaneous injection. The dose may be increased at 4- to 8-week intervals according to individual patient requirements to not more than 0.08 mg/kg/week. Clinical response, side effects, and determination of age- and gender-adjusted serum IGF-I levels may be used as guidance in dose titration. Alternatively, taking into account recent literature, a starting dose of approximately 0.2 mg/day (range, 0.15-0.30 mg/day) may be used without consideration of body weight. This dose can be increased gradually every 1-2 months by increments of approximately 0.1 to 0.2 mg/day, according to individual patient requirements based on the clinical response and serum IGF-I concentrations. During therapy, the dose should be decreased if required by the occurrence of adverse events and/or serum IGF-I levels above the age- and gender-specific normal range. Maintenance dosages vary considerably from person to person. A lower starting dose and smaller dose increments should be considered for older patients, who are more prone to the adverse effects of somatropin than younger individuals. In addition, obese individuals are more likely to manifest adverse effects when treated with a weight-based regimen. In order to reach the defined treatment goal, estrogen-replete women may need higher doses than men. Oral estrogen administration may increase the dose requirements in women.
Acute Critical Illness Children with Prader-Willi Syndrome who are severely obese or have severe respiratory impairment—reports of sudden death Active Malignancy Active Proliferative or Severe Non-Proliferative Diabetic Retinopathy Children with closed epiphyses Known hypersensitivity to somatropin or excipients
Drug Precautions ::
Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk Prader-Willi Syndrome in children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment. Discontinue treatment if these signs occur Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin–in particular meningiomas in patients treated with radiation to the head for their first neoplasm Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked. Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome, especially in adults): May occur frequently. Reduce dose as necessary Hypopituitarism: Closely monitor other hormone replacement therapies Hypothyroidism: May first become evident or worsen Slipped Capital Femoral Epiphysis: May develop. Evaluate children with the onset of a limp or hip/knee pain Progression of Preexisting Scoliosis: May develop Otitis Media and Cardiovascular Disorders in Turner syndrome: Patients with Turner syndrome should be evaluated for otitis media and other ear disorders and monitored for cardiovascular disorders Pancreatitis: Consider pancreatitis in patients with persistent severe abdominal pain, especially children Adverse events and death associated with benzyl alcohol: Formulations containing benzyl alcohol (5 mg/1.5 mL Omnitrope Cartridges and the Bacteriostatic Water for Injection diluent for the O
Drug Side Effects ::
Injection site reactions/rashes and lipoatrophy and headaches. Sudden death in pediatric patients with Prader-Willi Syndrome with risk factors including severe obesity, history of upper airway obstruction or sleep apnea and unidentified respiratory infection Intracranial tumors, in particular meningiomas, in teenagers/young adults treated with radiation to the head as children for a first neoplasm and somatropin. Glucose intolerance including impaired glucose tolerance/impaired fasting glucose as well as overt diabetes mellitus. Intracranial hypertension. Fluid retention manifested by edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paraesthesias. Pancreatitis.
Pregnancy category ::
Drug Mode of Action ::
Somatropin is a synthetic human growth hormone of recombinant DNA origin. It stimulates skeletal and soft tissue growth by promoting cell division, amino acid uptake and protein synthesis. It also possesses both insulin-like and diabetogenic effects.
Drug Interactions ::